Market Cap 12.57B
Revenue (ttm) 14.74B
Net Income (ttm) -634.20M
EPS (ttm) N/A
PE Ratio 4.73
Forward PE 4.77
Profit Margin -4.30%
Debt to Equity Ratio 1.07
Volume 7,397,900
Avg Vol 9,821,342
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 59%
Beta 0.90
Analysts Sell
Price Target $12.16

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 724 514 1800
Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:16 AM
$VTRS is currently trading at $10.72, showing a moderate RSI of 55.14, indicating a neutral to slightly bullish momentum. The price is above both the 30-day MA of $10.32 and the 50-day MA of $10.15, suggesting a positive short to medium-term trend. The recent high of $11.28 and low of $9.43 over the last 60 days indicate a range that supports potential upward movement, especially given the current position near the upper range. Directional bias is bullish due to the RSI being above 50 and the price trading above key moving averages. Suggested entry point is at $10.75, with a stop loss at $10.40 to manage risk. Target 1 is set at $11.00, just below the recent high, while Target 2 is at $11.25, allowing for further upside potential. This plan capitalizes on the current trend while managing risk effectively. https://privateprofiteers.com
0 · Reply
ItsCarRamRod
ItsCarRamRod Nov. 14 at 2:46 PM
$VTRS big gap to fill back to $10.00
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:50 AM
$VTRS: The stock is currently trading at $10.91, showing a positive market context with an RSI of 60.0, indicating a moderately bullish momentum. The 30-day moving average (MA30) at $10.3 and the 50-day moving average (MA50) at $10.14 suggest a strong upward trend, as the current price is above both MAs. The recent high of $11.28 and low of $9.43 over the last 60 days indicates a range that supports potential upward movement. Directional bias is bullish due to the RSI being below overbought territory and the price being well above both MAs. Suggested entry: $10.95 (slightly above the last close). Stop: $10.50 (to limit downside risk). Targets: $11.20 (near the 60D high) and $11.50 (a psychological level). This trade plan capitalizes on the current bullish sentiment while managing risk effectively. https://privateprofiteers.com
0 · Reply
BuyHighSellLowGER
BuyHighSellLowGER Nov. 13 at 9:56 PM
$VTRS Gimme another 15-20% so I can clean up my portfolio from meaningless positions.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Nov. 13 at 2:14 PM
$VTRS RSI: 62.77, MACD: 0.1696 Vol: 0.29, MA20: 10.41, MA50: 10.13 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:56 AM
$VTRS is currently trading at $11.2, with an RSI of 64.91 indicating it is approaching overbought territory. The 30-day moving average (MA30) at $10.24 and the 50-day moving average (MA50) at $10.12 suggest a bullish trend, as the price is well above these averages. The recent 60-day high of $11.28 presents a resistance level, while the low of $9.43 indicates a solid support zone. Given the current context, the directional bias is cautiously bullish, but the RSI suggests potential for a pullback. A suggested entry point is at $11.0, just below the current price, to capture potential upside. A stop loss can be placed at $10.80 to limit risk. Targets can be set at $11.28 (60D high) and $11.50, allowing for profit-taking as the price approaches resistance levels. Monitor for any signs of reversal as the RSI approaches overbought levels. https://privateprofiteers.com
0 · Reply
Kaerasori
Kaerasori Nov. 12 at 4:42 PM
$VTRS underpeformed ever since pfizer dumped its declining assets and created a toxic marriage with mylan. They messed up in India too and are melting in every business segment. I would pick Teva if forced to buy one.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:33 AM
$VTRS is currently trading at $11.2, with an RSI of 64.91 indicating it is approaching overbought territory. The 30-day moving average (MA30) at $10.24 and the 50-day moving average (MA50) at $10.12 suggest a bullish trend, as the price is well above these averages. The recent 60-day high of $11.28 presents a resistance level, while the low of $9.43 indicates a solid support zone. Given the current context, the directional bias is cautiously bullish, but the RSI suggests potential for a pullback. A suggested entry point is at $11.0, just below the current price, to capture potential upside. A stop loss can be placed at $10.80 to limit risk. Targets can be set at $11.28 (60D high) and $11.50, allowing for profit-taking as the price approaches resistance levels. Monitor for any signs of reversal as the RSI approaches overbought levels. https://privateprofiteers.com
0 · Reply
HarveyToronto
HarveyToronto Nov. 11 at 8:49 PM
$MQ Tired of winning? $PG $RIVN $VTRS
0 · Reply
tanner12oz
tanner12oz Nov. 11 at 8:25 PM
$VTRS what a move today...earnings drop made no sense..hopefully you added on the drop and didnt panic
1 · Reply
Latest News on VTRS
Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:46 PM EST - 8 days ago

Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript


Viatris Announces Quarterly Dividend

Nov 4, 2025, 6:59 AM EST - 10 days ago

Viatris Announces Quarterly Dividend


Viatris to Participate in Upcoming Investor Conferences

Oct 13, 2025, 6:59 AM EDT - 4 weeks ago

Viatris to Participate in Upcoming Investor Conferences


Viatris: Indore Plant Could Boost 2026 Numbers

Sep 25, 2025, 1:16 PM EDT - 7 weeks ago

Viatris: Indore Plant Could Boost 2026 Numbers


Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 11:02 AM EDT - 3 months ago

Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript


Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Jul 18, 2025, 2:17 PM EDT - 4 months ago

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review


Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 7:07 AM EDT - 4 months ago

Viatris eye therapy fails to meet late-stage trial goal


Viatris: A Contrarian Bet With Virtually No Downside

Jul 16, 2025, 3:19 AM EDT - 4 months ago

Viatris: A Contrarian Bet With Virtually No Downside


PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:16 AM
$VTRS is currently trading at $10.72, showing a moderate RSI of 55.14, indicating a neutral to slightly bullish momentum. The price is above both the 30-day MA of $10.32 and the 50-day MA of $10.15, suggesting a positive short to medium-term trend. The recent high of $11.28 and low of $9.43 over the last 60 days indicate a range that supports potential upward movement, especially given the current position near the upper range. Directional bias is bullish due to the RSI being above 50 and the price trading above key moving averages. Suggested entry point is at $10.75, with a stop loss at $10.40 to manage risk. Target 1 is set at $11.00, just below the recent high, while Target 2 is at $11.25, allowing for further upside potential. This plan capitalizes on the current trend while managing risk effectively. https://privateprofiteers.com
0 · Reply
ItsCarRamRod
ItsCarRamRod Nov. 14 at 2:46 PM
$VTRS big gap to fill back to $10.00
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:50 AM
$VTRS: The stock is currently trading at $10.91, showing a positive market context with an RSI of 60.0, indicating a moderately bullish momentum. The 30-day moving average (MA30) at $10.3 and the 50-day moving average (MA50) at $10.14 suggest a strong upward trend, as the current price is above both MAs. The recent high of $11.28 and low of $9.43 over the last 60 days indicates a range that supports potential upward movement. Directional bias is bullish due to the RSI being below overbought territory and the price being well above both MAs. Suggested entry: $10.95 (slightly above the last close). Stop: $10.50 (to limit downside risk). Targets: $11.20 (near the 60D high) and $11.50 (a psychological level). This trade plan capitalizes on the current bullish sentiment while managing risk effectively. https://privateprofiteers.com
0 · Reply
BuyHighSellLowGER
BuyHighSellLowGER Nov. 13 at 9:56 PM
$VTRS Gimme another 15-20% so I can clean up my portfolio from meaningless positions.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Nov. 13 at 2:14 PM
$VTRS RSI: 62.77, MACD: 0.1696 Vol: 0.29, MA20: 10.41, MA50: 10.13 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:56 AM
$VTRS is currently trading at $11.2, with an RSI of 64.91 indicating it is approaching overbought territory. The 30-day moving average (MA30) at $10.24 and the 50-day moving average (MA50) at $10.12 suggest a bullish trend, as the price is well above these averages. The recent 60-day high of $11.28 presents a resistance level, while the low of $9.43 indicates a solid support zone. Given the current context, the directional bias is cautiously bullish, but the RSI suggests potential for a pullback. A suggested entry point is at $11.0, just below the current price, to capture potential upside. A stop loss can be placed at $10.80 to limit risk. Targets can be set at $11.28 (60D high) and $11.50, allowing for profit-taking as the price approaches resistance levels. Monitor for any signs of reversal as the RSI approaches overbought levels. https://privateprofiteers.com
0 · Reply
Kaerasori
Kaerasori Nov. 12 at 4:42 PM
$VTRS underpeformed ever since pfizer dumped its declining assets and created a toxic marriage with mylan. They messed up in India too and are melting in every business segment. I would pick Teva if forced to buy one.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:33 AM
$VTRS is currently trading at $11.2, with an RSI of 64.91 indicating it is approaching overbought territory. The 30-day moving average (MA30) at $10.24 and the 50-day moving average (MA50) at $10.12 suggest a bullish trend, as the price is well above these averages. The recent 60-day high of $11.28 presents a resistance level, while the low of $9.43 indicates a solid support zone. Given the current context, the directional bias is cautiously bullish, but the RSI suggests potential for a pullback. A suggested entry point is at $11.0, just below the current price, to capture potential upside. A stop loss can be placed at $10.80 to limit risk. Targets can be set at $11.28 (60D high) and $11.50, allowing for profit-taking as the price approaches resistance levels. Monitor for any signs of reversal as the RSI approaches overbought levels. https://privateprofiteers.com
0 · Reply
HarveyToronto
HarveyToronto Nov. 11 at 8:49 PM
$MQ Tired of winning? $PG $RIVN $VTRS
0 · Reply
tanner12oz
tanner12oz Nov. 11 at 8:25 PM
$VTRS what a move today...earnings drop made no sense..hopefully you added on the drop and didnt panic
1 · Reply
HarveyToronto
HarveyToronto Nov. 11 at 8:19 PM
Feeling good to be ahead of the market with $VTRS.
0 · Reply
PetrCZE
PetrCZE Nov. 11 at 7:41 AM
$VTRS At least the drop after this earnings was milder than after previous releases. Company seems to be in the best shape in several years (divestitures help to reduce the debt and now cash flow can be used for new invest) Still, market is waiting on Y/Y growth ... hope this comes with Indore plant reopen in 2026 (potential up to +500mil to annual sales) and with new acquisitions. Once Y/Y sales growth is reported, the P/E valuation would start to shift to the industry average and the SP growth might be significant to 20+. But still might take up to several years from now till we are there. Meanwhile, I will keep taking dividends and will be sitting on my shares...
0 · Reply
Zonata
Zonata Nov. 7 at 6:11 PM
$VTRS results were outstanding, yet market is punishing this?
0 · Reply
d_risk
d_risk Nov. 7 at 12:09 AM
$VTRS - Viatris Inc. Common Stock - 10Q - Updated Risk Factors Viatris warns new tariffs, trade restrictions, or domestic sourcing rules—and any retaliation—could materially hit its business, financials, cash flow, dividends, and stock price. #Pharmaceuticals #MarketVolatility #FinancialRisk #TariffsImpact #TradeRestrictions 🟢 Added 🟠 Removed https://d-risk.ai/VTRS/10-Q/2025-11-06
1 · Reply
ItsCarRamRod
ItsCarRamRod Nov. 6 at 9:14 PM
$VTRS -6% in VTRS is just called a good start
0 · Reply
Estimize
Estimize Nov. 6 at 8:23 PM
$VTRS reported 0.67 EPS and 3,760 revenue for Q3. http://www.estimize.com/intro/vtrs?chart=historical&metric_name=eps&utm_content=VTRS&utm_
0 · Reply
juzbeachy
juzbeachy Nov. 6 at 4:16 PM
$VTRS Solid quarter here. Profitability declined mainly from foreign exchange, divestitures, and the “Indore impact” (loss of certain manufacturing output from its India site). I think if they changed their name from Viatras to V“AI”tris the stock would be trading t $30.
0 · Reply
ZacksResearch
ZacksResearch Nov. 6 at 3:50 PM
$VTRS beats Q3 expectations, but is it enough to sustain momentum? 📈 Despite adjusted EPS of 67 cents topping the Zacks Consensus Estimate, total revenues fell 2% on an operational basis. The stock is down 13.3% YTD, lagging behind the industry’s 2.8% gain. Discover the full story here 👉 https://www.zacks.com/stock/news/2786980/viatris-tops-q3-earnings-revenue-estimates-ups-25-guidance?cid=sm-stocktwits-2-2786980-body-19809&ADID=SYND_STOCKTWITS_TWEET_2_2786980_BODY_19809
0 · Reply
ItsCarRamRod
ItsCarRamRod Nov. 6 at 3:47 PM
$VTRS average day down for VTRS
0 · Reply
ZacksResearch
ZacksResearch Nov. 6 at 2:50 PM
$VTRS delivers a clean beat and raises the bar for 2025. 📈 Q3 earnings and revenue topped estimates, full-year guidance was lifted, and the company strengthened its Japan footprint with the Aculys Pharma deal. Full details here 👉 https://www.zacks.com/stock/news/2786980/viatris-tops-q3-earnings-revenue-estimates-ups-25-guidance?cid=sm-stocktwits-2-2786980-teaser-19808&ADID=SYND_STOCKTWITS_TWEET_2_2786980_TEASER_19808
0 · Reply
PetrCZE
PetrCZE Nov. 6 at 12:30 PM
$VTRS Found the update on Indore in their presentation: Our initial remediation activities are substantially complete, and we recently met with the U.S. FDA to discuss our remediation progress and potential timing for reinspection Continue to build operational redundancies by requalifying other sites in our network and adding third-party suppliers for products manufactured at Indore -> no concrete timing known yet, when issue to be resolved...
0 · Reply
PetrCZE
PetrCZE Nov. 6 at 12:22 PM
$VTRS Is it known, what is the expected additional annual revenue from the recently announced acquisitions of Aculys and Spydia?
0 · Reply